**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Alessandra Corazza
Department of Medicine
University of Udine
Udine
Italy
E.mail: alessandra.corazza@uniud.it

**Main Body of the Abstract**
Transthyretin (TTR)-related amyloidosis (ATTR) is a systemic disease characterized by the accumulation of TTR in insoluble amyloid fibers. ATTR is a progressive and ultimately fatal disease, with approximately 130 mutations associated with the rare inherited forms of the disease. The predominant manifestations are typically polyneuropathic or cardiac, with an average age of onset of 39 years. Different mutations lead to different phenotypes and varying degrees of disease severity.
This research focuses on two amyloidogenic variants, Val122Ile (V122I) and Ser52Pro (S52P), compared to wild-type TTR (WT-TTR) and the protective form T119M. V122I is associated with late-onset cardiomyopathy, while S52P is associated with early-onset aggressive polyneuropathy with subsequent cardiomyopathy. Although all variants were subjected to structural characterization using X-rays, no significant differences to WT-TTR were found.
To further investigate the structural aspects and dynamics of the protein, in particular the fast and slow movements and the population of the different conformers, nuclear magnetic resonance (NMR) is used in this study. In addition, the effect of stabilizers in different variants is also addressed. NMR provides unique insights into these structural details and helps to understand the different pathological outcomes, both in terms of prognosis and organ involvement.



NMR reveals structural and dynamics changes of transthyretin that were hidden in X-ray studies OB13 (#449)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.